| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24d6118e8f347dc2b44ec3ac859cd824 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfaca2fc9b5dc40dd1d70eb0402e5e65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bb33b78643b08f1c09e4d0e6ca67020
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_498cc51fb43305fe867a64342af658ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72f6c1500838c6dbb473d3eb995ee95 |
| publicationDate |
2022-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11439608-B2 |
| titleOfInvention |
Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| abstract |
Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021261917-A1 |
| priorityDate |
2017-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |